US2007155795A1PendingUtilityA1
Muscarinic agonists
Est. expiryApr 28, 2020(expired)· nominal 20-yr term from priority
Inventors:Carl-Magnus A. AnderssonBo Lennart Mikael FribergNiels SkjaerbaekTracy SpaldingAllan K. Uldam
A61P 43/00C07D 401/06C07D 413/06A61P 25/04A61P 25/14A61P 25/16C07D 409/06A61P 25/20A61P 27/02C07D 413/12A61P 25/24C07D 471/04C07D 487/04C07D 473/00A61P 25/18C07D 417/06C07D 405/06A61P 29/00A61P 25/02A61P 25/28A61P 27/06
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
Claims
exact text as granted — not AI-modified1 - 76 . (canceled)
77 . A compound of formula (I):
wherein:
Z 1 is CR 1 , Z 2 is CR 2 , Z 3 is CR 3 , and Z 4 is CR 4 ;
W 1 is S, W 2 is N or CR 6 , and W 3 is CG;
G is of formula (II):
Y is O, S, CHOH, —NHC(O)—, —C(O)NH—, —C(O)—, —OC(O)—, —(O)CO—, —NR 7 —, —CH═N—, or absent;
p is 1, 2, 3, 4 or 5;
Z is CR 8 R 9 or absent;
each t is 1, 2, or 3;
each R 1 , R 2 , R 3 , and R 4 , independently, is H, amino, hydroxyl, halo, or straight- or branched-chain C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 heteroalkyl, C 1-6 haloalkyl, —CN, —CF 3 , —OR 11 , —COR 11 , —NO 2 , —SR 11 , —NHC(O)R 11 , —C(O)NR 12 R 13 , —NR 12 R 13 , NR 11 C(O)NR 12 R 13 , —SO 2 NR 12 R 13 , —OC(O)R 11 , —O(CH 2 ) q NR 12 R 13 , or —(CH 2 ) q NR 12 R 13 , where q is an integer from 2 to 6, or R 1 and R 2 together form —NH—N═N— or R 3 and R 4 together form —NH—N═N—;
each R 5 , R 6 , and R 7 , independently, is H, C 1-6 alkyl; formyl; C 3-6 cycloalkyl; C 5-6 aryl, optionally substituted with halo or C 1-6 alkyl; or C 5-6 heteroaryl, optionally substituted with halo or C 1-6 alkyl;
each R 8 and R 9 , independently, is H or straight- or branched-chain C 1-8 alkyl;
R 10 is straight- or branched-chain C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkylidene, C 1-8 alkoxy, or C 1-8 heteroalkyl;
R 10 ′ is H, straight- or branched-chain C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkylidene, C 1-8 alkoxy, C 1-8 heteroalkyl, C 1-8 aminoalkyl, C 1-8 haloalkyl, C 1-8 alkoxycarbonyl, C 1-8 hydroxyalkoxy, C 1-8 hydroxyalkyl, or C 1-8 alkylthio;
each R 11 , independently, is H, straight- or branched-chain C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 2-8 heteroalkyl, C 2-8 aminoalkyl, C 2-8 haloalkyl, C 1-8 alkoxycarbonyl, C 2-8 hydroxyalkyl, —C(O)—C 5-6 aryl substituted with C 1-3 alkyl or halo, C 5-6 aryl, C 5-6 heteroaryl, C 5-6 cycloalkyl, C 5-6 heterocycloalkyl, —C(O)NR 12 R 13 , —CR 5 R 12 R 13 , —(CH 2 ) t NR 12 R 13 , t is an integer from 2 to 8; and
each R 12 and R 13 , independently, is H, C 1-6 alkyl; C 3-6 cycloalkyl; C 5-6 aryl, optionally substituted with halo or C 1-6 alkyl; or C 5-6 heteroaryl, optionally substituted with halo or C 1-6 alkyl;
or a pharmaceutically acceptable salt, ester or prodrug thereof.
78 . The compound of claim 77 , wherein each t is 2.
79 . The compound of claim 78 , wherein R 10 is n-butyl.
80 . The compound of claim 78 , wherein each R 1 , R 2 , R 3 , and R 4 , independently, is H, hydroxyl, halo, C 1-6 heteroalkyl, CF 3 , —NO 2 , or straight- or branched-chain C 1-6 alkyl, or R 1 and R 2 together form —NH—N═N— or R 3 and R 4 together form —NH—N═N—.
81 . The compound of claim 78 , wherein Y is absent or O, p is 0, 1, 2 or 3, and R 8 and R 9 are H.
82 . The compound of claim 81 , wherein Z is absent, Y is absent and p is 3.
83 . The compound of claim 82 , wherein R 10 is n-butyl.
84 . The compound of claim 77 , wherein the compound is:
1-benzo[b]thiophen-2-yl-4-(4-butylpiperidin-1-yl)-butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(5-fluoro-3-methyl-benzo[b]thiophen-2-yl)-butan-1-one; 1-(3-bromo-benzo[b]thiophen-2-yl)-4-(4-butylpiperidin-1-yl)-butan-1-one 1-(3-benzo[b]thiophen-2-yl-propyl)-4-butylpiperidine; 4-butyl-1-[3-(5-fluoro-3-methyl-benzo[b]thiophen-2-yl)-propyl]-piperidine; 1-(3-benzo [b]thiophen-2-yl-propyl)-4-methylpiperidine 1-(3-benzo[b]thiophen-2-yl-propyl)-4-benzylpiperidine; or 3-[3-(4-butyl-piperidin-1-yl)-propyl]-benzo[d]isothiazole.
85 . A pharmaceutical composition comprising an effective amount of a compound of formula (I):
wherein:
Z 1 is CR 1 , Z 2 is CR 2 ,Z 3 is CR 3 , and Z 4 is CR 4 ;
W 1 is S, W 2 is N or CR 6 , and W 3 is CG;
G is of formula (II):
Y is O, S, CHOH, —NHC(O)—, —C(O)NH—, —C(O)—, —OC(O)—, —(O)CO—, —NR 7 —, —CH═N—, or absent;
p is 1, 2, 3, 4 or 5;
Z is CR 8 R 9 or absent;
each t is 1, 2, or 3;
each R 1 , R 2 , R 3 , and R 4 , independently, is H, amino, hydroxyl, halo, or straight- or branched-chain C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 heteroalkyl, C 1-6 haloalkyl, —CN, —CF 3 , —OR 11 , —COR 11 , —NO 2 , —SR 11 , —NHC(O)R 11 , —C(O)NR 12 R 13 , —NR 12 R 13 , NR 11 C(O)NR 12 R 13 , —SO 2 NR 12 R 13 , —OC(O)R 11 , —O(CH 2 ) q NR 12 R 13 , or —(CH 2 ) q NR 12 R 13 , where q is an integer from 2 to 6, or R 1 and R 2 together form —NH—N═N— or R 3 and R 4 together form —NH—N═N—;
each R 5 , R 6 , and R 7 , independently, is H, C 1-6 alkyl; formyl; C 3-6 cycloalkyl; C 5-6 aryl, optionally substituted with halo or C 1-6 alkyl; or C 5-6 heteroaryl, optionally substituted with halo or C 1-6 alkyl;
each R 8 and R 9 , independently, is H or straight- or branched-chain C 1-8 alkyl;
R 10 is straight- or branched-chain C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkylidene, C 1-8 alkoxy, or C 1-8 heteroalkyl;
R 10 ′ is H, straight- or branched-chain C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkylidene, C 1-8 alkoxy, C 1-8 heteroalkyl, C 1-8 aminoalkyl, C 1-8 haloalkyl, C 1-8 alkoxycarbonyl, C 1-8 hydroxyalkoxy, C 1-8 hydroxyalkyl, or C 1-8 alkylthio;
each R 11 , independently, is H, straight- or branched-chain C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 2-8 heteroalkyl, C 2-8 aminoalkyl, C 2-8 haloalkyl, C 1-8 alkoxycarbonyl, C 2-8 hydroxyalkyl, —C(O)—C 5-6 aryl substituted with C 1-3 alkyl or halo, C 5-6 aryl, C 5-6 heteroaryl, C 5-6 cycloalkyl, C 5-6 heterocycloalkyl, —C(O)NR 12 R 13 , —CR 5 R 12 R 13 , —(CH 2 ) t NR 12 R 13 , t is an integer from 2 to 8; and
each R 12 and R 1-3 , independently, is H, C 1-6 alkyl; C 3-6 cycloalkyl; C 5-6 aryl, optionally substituted with halo or C 1-6 alkyl; or C 5-6 heteroaryl, optionally substituted with halo or C 1-6 alkyl;
or a pharmaceutically acceptable salt, ester or prodrug thereof.
86 . A pharmaceutical composition of claim 85 , wherein each t is 2.
87 . A pharmaceutical composition of claim 86 , wherein R 10 is n-butyl.
88 . A pharmaceutical composition of claim 86 , wherein each R 1 , R 2 , R 3 , and R 4 , independently, is H, hydroxyl, halo, C 1-6 heteroalkyl, CF 3 , —NO 2 , or straight- or branched-chain C 1-6 alkyl, or R 1 and R 2 together form —NH—N═N— or R 3 and R 4 together form —NH—N═N—.
89 . A pharmaceutical composition of claim 86 , wherein Y is absent or O, p is 0, 1, 2 or 3, and R 8 and R 9 are H.
90 . A pharmaceutical composition of claim 89 , wherein Z is absent, Y is absent and p is 3.
91 . A pharmaceutical composition of claim 90 , wherein R 10 is n-butyl.
92 . A pharmaceutical composition of claim 86 , wherein the compound is:
1-benzo[b]thiophen-2-yl-4-(4-butylpiperidin-1-yl)-butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(5-fluoro-3-methyl-benzo [b]thiophen-2-yl)-butan-1-one; 1-(3-bromo-benzo [b]thiophen-2-yl)-4-(4-butylpiperidin-1-yl)-butan-1-one 1-(3-benzo [b]thiophen-2-yl-propyl)-4-butylpiperidine; 4-butyl-1-[3-(5-fluoro-3-methyl-benzo [b]thiophen-2-yl)-propyl]-piperidine; 1-(3-benzo [b]thiophen-2-yl-propyl)-4-methylpiperidine; 1-(3-benzo[b]thiophen-2-yl-propyl)-4-benzylpiperidine; or 3-[3-(4-butyl-piperidin-1-yl)-propyl]-benzo[d]isothiazole.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.